An effective vaccine against toxoplasmosis is suggested to be based on the proposed model of protective immunity, dependent on the activation of the cellular immune response (Th1) with cytotoxic CD8 + T lymphocytes [21] and efficient induction of specific CD4 + T cells, both of which participate in protection through the secretion of effector and inflammatory cytokines such as IFN-γ, TNF-α, IL-1, and IL-6 [22]. The gene discussed is IFNG; the disease is toxoplasmosis.